NasdaqGS - Delayed Quote USD

Atea Pharmaceuticals, Inc. (AVIR)

3.6500

-0.0500

(-1.35%)

At close: May 17 at 4:00 PM EDT

3.6306

-0.02

(-0.53%)

Pre-Market: 8:00 AM EDT

Key Events

Loading Chart for AVIR

9/21 12:03 PM

DELL

Previous Close 3.7000
Open 3.7200
Bid 3.6200 x 100
Ask 3.7000 x 100
Day's Range 3.6450 - 3.7556
52 Week Range 2.7650 - 5.1900
Volume 320,359
Avg. Volume 314,554
Market Cap (intraday) 307.414M
Beta (5Y Monthly) 0.19
PE Ratio (TTM) --
EPS (TTM) -1.9500
Earnings Date Aug 6, 2024 - Aug 12, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 3.00

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

74

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVIR

19.67%

S&P 500

11.18%

1-Year Return

AVIR

5.49%

S&P 500

29.04%

3-Year Return

AVIR

84.07%

S&P 500

27.06%

5-Year Return

AVIR

86.50%

S&P 500

62.18%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Atea Pharmaceuticals, Inc.

3.6500

-1.35%

Mkt Cap 307.414M

Industry Biotechnology

Theravance Biopharma, Inc.

9.29

-3.23%

Mkt Cap 451.802M

Industry Biotechnology

Instil Bio, Inc.

11.50

-2.54%

Mkt Cap 74.795M

Industry Biotechnology

0.7754

+3.19%

Mkt Cap 89.173M

Industry Biotechnology

1.6500

-1.79%

Mkt Cap 19.185M

Industry Biotechnology

Assembly Biosciences, Inc.

14.53

-1.29%

Mkt Cap 80.108M

Industry Biotechnology

Achilles Therapeutics plc

0.9478

+1.03%

Mkt Cap 40.475M

Industry Biotechnology

Cellectar Biosciences, Inc.

3.3000

-0.90%

Mkt Cap 118.301M

Industry Biotechnology

Spero Therapeutics, Inc.

1.5900

+1.27%

Mkt Cap 85.839M

Industry Biotechnology

27.18

-1.16%

Mkt Cap EUR 1.791B

Industry Biotechnology

Aligos Therapeutics, Inc.

0.6885

+5.11%

Mkt Cap 53.779M

Industry Biotechnology

Valuation Measures

As of 5/17/2024

Market Cap

307.41M
Enterprise Value

-231.86M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

0.61
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-15.56%
Return on Equity (ttm)

-29.16%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-163.66M
Diluted EPS (ttm)

-1.9500

Balance Sheet and Cash Flow

Total Cash (mrq)

541.49M
Total Debt/Equity (mrq)

0.44%
Levered Free Cash Flow (ttm)

-9.22M

AVIR does not have Company Insights

ATHA Athira Pharma, Inc.

2.5200

-7.01%

KOD Kodiak Sciences Inc.

3.3000

-11.76%

PRLD Prelude Therapeutics Incorporated

4.0000

-6.54%

ALLK Allakos Inc.

1.4400

-0.69%

ITOS iTeos Therapeutics, Inc.

18.05

+0.84%

ALLO Allogene Therapeutics, Inc.

2.7700

-7.97%

SEER Seer, Inc.

2.1100

-0.47%

CCCC C4 Therapeutics, Inc.

5.68

-4.86%

ALXO ALX Oncology Holdings Inc.

14.21

-3.07%

FHTX Foghorn Therapeutics Inc.

5.51

-5.16%

KYMR Kymera Therapeutics, Inc.

34.95

-1.83%

MRVI Maravai LifeSciences Holdings, Inc.

11.32

+1.98%

ALEC Alector, Inc.

5.44

-0.91%

OM Outset Medical, Inc.

3.6100

+2.56%

BBIO BridgeBio Pharma, Inc.

30.09

-3.06%

BCAB BioAtla, Inc.

2.8300

-8.71%